Amryt acquires Aegerion Pharmaceuticals .

Amryt, a biopharmaceutical company focused on rare and orphan diseases, announces that it has reached agreement to acquire Aegerion Pharmaceuticals , a subsidiary of Novelion Therapeutics Inc.. The transaction has been unanimously approved and recommended by the Boards of Amryt, Aegerion and Novelion. Amryt has built a diversified portfolio of drugs to treat patients with rare and orphan diseases through the acquisition of its AP 101 and AP 103 product lines and through the in-licencing of the Lojuxta product line. The transaction is in line with the Company's strategy to expand its product portfolio to enhance shareholder value. The main product of Aegerion is Myalept, a treatment for Liposdystrophy which was FDA approved in 2014.